Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can cash rewards and a breathalyzer app help people stay sober?

NCT ID NCT07735585

Disease control Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial tests whether a smartphone app called TRIS, paired with a Bluetooth breathalyzer and small daily cash rewards for verified abstinence, can help people with alcohol use disorder drink less. Participants submit three breath samples each day; those who are sober earn incentives. The study compares this approach to standard outpatient treatment alone. If it works, the app could make evidence-based sobriety support more accessible from home.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Remote contingency management delivered through a smartphone app with a Bluetooth breathalyzer and monetary incentives for verified abstinence
What this could lead to
If effective, this app-based approach could offer a scalable, convenient way to support sobriety for people with alcohol use disorder, potentially expanding access to evidence-based behavioral treatment.
What could go wrong
The trial is relatively small (130 participants) and relies on self-submitted breath samples, which may not capture all drinking episodes. The monetary incentives may not be sustainable in real-world settings, and results may not generalize beyond the Brazilian outpatient context.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to read and speak Portuguese. * Provide signed informed consent. * Age 18 to 70 years. * Alcohol consumption within the past month. * Current diagnosis of Alcohol Use Disorder (AUD). * Seeking treatment for AUD at AME Vila Maria or Instituto Perdizes. * Breath alcohol concentration (BrAC) of 0.00 at the time of consent. * Own and be able to operate a smartphone with an active mobile service plan. * Smartphone compatible with the Bluetooth frequency required for the BACtrack breathalyzer. Exclusion Criteria: * Crack cocaine use within the past 90 days. * Any seizure episode within the past 12 months. * Diagnosis of a psychotic disorder (DSM-5). * Suicide attempt within the past two years. * Any medical or psychiatric condition that may compromise safe participation, as determined by the study medical director.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcohol use disorder (AUD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcohol abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alcohol use disorder (AUD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IPER Research Center

    RECRUITING

    São Paulo, São Paulo, 05021-001, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.